LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Lexaria Bioscience Corp.
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026
$2.60−0.26 (-9.09%)
Close on Oct 19, 2026
- Market cap
- $64.50M
- P/E (TTM)
- –
- Dividend yield
- –
Lexaria Bioscience Corp. revenue by segment
By business segment
| Revenue | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IP Licensing [Member] | $194.00K | $368.00K | $522.00K | $696.00K | $606.00K | $516.00K | $487.00K | $457.99K | $415.86K | $356.48K | $228.36K | $146.80K | 100.0% | -68.0% |
| Corporate | – | – | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | – | – |
By product or service
| Revenue | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IP Licensing [Member] | $194.00K | $368.00K | $522.00K | $696.00K | $606.00K | $516.00K | – | $457.99K | – | – | – | – | 100.0% | -68.0% |
| B2B [Member] | $0 | $0 | $0 | $9.92K | $9.92K | $9.92K | – | $5.39K | – | – | – | – | 0.0% | -100.0% |
| R&D [Member] | – | – | – | – | $0 | $0 | $0 | $900 | – | – | – | – | – | – |
| Other [Member] | – | – | – | $0 | – | – | – | $900 | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Lexaria Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.